Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment

Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study

(2017) Wai-Kay Seto et al.   HEPATOLOGY

Emerging treatments for classical myeloproliferative neoplasms

(2016) Alessandro M. Vannucchi et al.   BLOOD

Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib

(2016) Keita Kirito et al.   INTERNAL MEDICINE

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

(2015) R Zeiser et al.   LEUKEMIA

Immunological Consequences of JAK Inhibition: Friend or Foe?

(2015) Donal P. McLornan et al.   Current Hematologic Malignancy Reports

Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study

(2014) Wai-Kay Seto et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatitis B virus reactivation associated with ruxolitinib

(2013) Chien-Heng Shen et al.   ANNALS OF HEMATOLOGY

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis

(2013) G Caocci et al.   LEUKEMIA

Management of patients with hepatitis B who require immunosuppressive therapy

(2013) Jessica P. Hwang et al.   Nature Reviews Gastroenterology & Hepatology

HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma

(2008) Man–Fung Yuen et al.   GASTROENTEROLOGY